The uptake and processing of glucagon into liver endosomes were studied in vivo by subcellular fractionation. After injection of [[125I]iodo-Tyr10]glucagon and [[125I]iodo-Tyr13]glucagon to rats, the uptake of radioactivity into the liver was maximum at 2 min (6 % of the dose/g of tissue). On differential centrifugation, the radioactivity in the homogenate was recovered mainly in the nuclear (N), microsomal (P) and supernatant (S) fractions, with maxima at 5, 10 and 40 min, respectively; recovery of radioactivity in the mitochondrial-lysosomal (ML) fraction did not exceed 6 % and was maximal at 20 min. On density-gradient centrifugation, the radioactivity associated first (2-10 min) with plasma membranes and then (10-40 min) with Golgi-endosomal (GE) fractions, with 2-5-fold and 20-150-fold enrichments respectively. Subfractionation of the GE fractions showed that, unlike the Golgi marker galactosyltransferase, the radioactivity was density-shifted by diaminobenzidine cytochemistry. Subfractionation of the ML fraction isolated at 40 min showed that more than half of the radioactivity was recovered at lower densities than the lysosomal marker acid phosphatase.
INTRODUCTION
It is now well established that, upon interaction with the hepatocyte, its major target cell, glucagon undergoes receptormediated endocytosis and degradation [1] [2] [3] [4] [5] . However, the subcellular sites at which glucagon degradation occurs, and the role of endocytosis in glucagon degradation, are not yet firmly established. Studies on intact isolated hepatocytes have enabled the identification of two pathways of glucagon degradation: one chloroquine-sensitive pathway, shown to result in the cleavage of glucagon to low-molecular-mass peptides and suggested to occur in lysosomes [6] ; and one chloroquine-insensilive pathway, shown to result in the removal of the three N-terminal residues of the hormone and suggested to occur in a superficial region of the hepatocyte [3] . Studies with isolated liver plasma membranes have shown that, after binding to its receptor, glucagon is processed to fragments that remain in part membrane-associated [7, 8] ; the Tyr'3-Leu"4 bond was identified as one major site of cleavage [9] .
Previous studies using subcellular fractionation have shown that, upon uptake by the liver in vivo, [1251] iodoglucagon undergoes progressive accumulation in low-density endocytic structures physically distinct from lysosomes [10, 11] . It was also shown that the [1251] iodoglucagon associated with these structures retained apparent integrity [11] , making their involvement in glucagon degradation questionable. However, those studies used analytical methods that would not have allowed the detection of subtle changes in the glucagon molecule.
In the present study, the uptake in vivo of [125I]iodoglucagon into liver endocytic structures has been studied by using Reverse-phase h.p.l.c. was performed on a Waters model 600 liquid chromatograph equipped with a model U6K sample injector fitted with a 1 ml loop, a guard column and an analytical micro Bondapak C18 column (0.4 cm x 30 cm; Waters), or an analytical Ultrasphere C18 ion-pairing column (5 ,um particle size; 0.46 cm x 25 cm; Beckman). Eluates were monitored online for A280 with a LC spectrophotometer and for radioactivity with a Berthold LB 504 gamma detector connected to an Apple Ile computer.
Automated Edman degradation was carried out on an Applied Biosystems sequenator model 470 A equipped with on-line identification of amino acid phenylthiohydantoins. At each cycle, the radioactivity released from ['25Iiodoglucagon or its degradation products was monitored.
Preparation, purification and characterization of
I1251liodoglucagon
[1251I]Iodoglucagon was prepared by using lactoperoxidase as described by Sonne et al. [12] , with a molar ratio of iodine to glucagon of 1:4. Routinely, incorporation of 1251 into peptide as determined by trichloroacetic acid (TCA) precipitation was in the range 60-80 %, corresponding to a specific radioactivity of 60-80 mCi/mg (about 0.2 atom of iodine per molecule).
Purification of radioiodinated products was achieved by reverse-phase h.p.l.c. in two steps. The iodination mixture was first chromatographed on an analytical micro Bondapak C18 column, with as eluent a mixture of 0.1 % TFA in water (solvent A) and 0.1 % TFA in acetonitrile (solvent B), pumped at a rate of 2 ml/min. Elution was carried out for 30 min with a linear gradient of 30-40% solvent B. The two major radioactive products in the eluate were collected and, after addition of BSA (1 %, w/v), freeze-dried. One of these products, which was eluted at 21 min (see the Results section), was further analysed by chromatography on an Ultrasphere C18 ion-pairing column exactly as described by Hagopian & Tager [2] . The two major products in the eluate were collected and freeze-dried.
The iodotyrosine composition of the radioiodinated products was assessed by Pronase hydrolysis, followed by chromatography on the micro Bondapak C18 column by isocratic elution with 15 % solvent B. The distribution of 1251 between Tyr'0 and Tyr13 ofglucagon was assessed by two independent methods: sequential trypsin and chymotrypsin hydrolysis, and radio-sequence analysis. Trypsin hydrolysis of [125Iiodoglucagons was carried out as described by Rojas et al. [13] . After isolation by h.p.l.c., the tryptic peptides were hydrolysed by chymotrypsin (0.1 mg/ml) in 25 mM-Tris/HCI buffer, pH 7.6, containing 1 mM-CaCl2 and 1 mg of BSA/ml for 16 h at 37°C, and re-chromatographed; column and elution conditions were as described for Pronase hydrolysates. Radio-sequence analysis was carried out by automated Edman degradation as described above.
The binding of [1251] iodoglucagon derivatives (0.01-1 nM) to liver plasma membranes was measured as described previously [14] , with results analysed in accordance with Scatchard [15] . Animals Livers were homogenized and submitted to subcellular fractionation by using established procedures with slight modifications [16] . To minimize the degradation of ['25Iliodoglucagon which occurs in homogenates during fractionation, N-ethylmaleimide (2 mM), bacitracin (1 mg/ml) and 1,10-phenanthroline (5 mM) were routinely included in the homogenization medium. Nuclear (N), mitochondrial-lysosomal (ML), microsomal (P) and supernatant (S) fractions were isolated from homogenates in 0.25 M-sucrose by differential centrifugation [171. Light (GEI), intermediate (GEi) and heavy (GEh) Golgi-endosomal fractions (respective densities 1.03-1.08, 1.08-1.11 and 1.11-1.18 g/cm3) were isolated from the microsomal fraction by discontinuous-density-gradient centrifugation [18] . Analytical subfractionation of Golgiendosomal fractions was performed by the diaminobenzidineinduced density-shift method of Courtoy et al. [19] . Plasma membranes were isolated from homogenates in 1 mM-bicarbonate as described by Neville [20] up to step 11. In some experiments, the ML fraction was subfractionated by centrifugation in analytical sucrose density gradients as described previously [16] . After isolation, subcellular fractions were resuspended in 5 [21] , with BSA as a standard. Acid phosphatase was assayed as described by Trouet [22] . Alkaline phosphodiesterase and Nacetyl-fl-D-glucosaminidase were assayed by the method of Touster et al. [23] , with 3 mM-p-nitrophenyl 5'-thymidylate and 6 mM-p-nitrophenyl N-acetyl-,8-D-glucosaminide as substrates respectively. Galactosyltransferase activity was measured as described by Beaufay et al. [24] , with ovalbumin as acceptor.
RESULTS

Purification and characterization of monol125Iliodoglucagon
Fractionation of the glucagon iodination mixture by reversephase h.p.l.c. on the C18 micro Bondapak column allowed the isolation of two major radioiodinated products, which were eluted at 14 and 21 min (Fig. 1, panel a) . These products were well resolved from native glucagon, which was eluted at 17 min. When individually collected and rechromatographed, products With trypsin hydrolysates, the radioactivity recovered in the h.p.l.c. eluate was equally distributed between two major components, with retention times of 3 and 8 min respectively. On rechromatography after chymotrypsin hydrolysis, the former was converted into an unknown product which was eluted at 7.5 min, whereas the latter was converted into a product which co-eluted with monoiodotyrosine. These results suggest that the tryptic peptides eluted at 3 and 8 min consist respectively of fragments 1-12 and 13-17 of glucagon, and that peak B consists of two equimolar populations of mono[125I]iodoglucagons labelled at positions 10 and 13.
Further purification of peak B was then achieved by h.p.l.c. on an Ultrasphere ion-pairing C18 column under the conditions described by Hagopian & Tager [2] . As expected, the radioactivity eluted from the column was equally distributed between two components (I and II), with retention times of 30 and 34 min ( Fig. 1, panel b) . Radio-sequence analysis showed that the radioactivity associated with these peptides was released during cycles 13 and 10 of Edman degradation respectively ( 
Biochemical characterization of liver subcellular fractions
Recoveries of protein and marker enzymes in liver subcellular fractions of normal rats are shown in Table 1 . The N and P fractions accounted together for 90% of alkaline phosphodiesterase, a plasma membrane marker; the ML Table 1 , the maximal enrichment in lysosomal markers in Golgi-endosomal fractions can be estimated as 3-fold, a value at least 20 times lower than that reported for purified lysosomes [25] . Plasma membranes accounted for about 10 % of alkaline phosphodiesterase, but for only 0.1 % of lysosomal markers. These data essentially agree with previously published studies [16, 17, 20, 25, 26] .
As previously reported [27] , chloroquine treatment led to a 2-fold increase in the recovery of acid phosphatase in Golgiendosomal fractions (results not shown).
Time course of uptake of 1125Iiodoglucagon into liver subcellular fractions of untreated and chloroquine-treated rats After injection of [1251] iodoglucagon, the uptake of radioactivity into liver homogenates was maximal at 2 min (Fig. 3) . At this time, about 0.03 % of the dose injected was recovered per mg of protein (about 6 % of the dose per g of liver). Homogenate radioactivity declined rapidly thereafter, with a half-life of about 10 min. At no time after injection did chloroquine treatment significantly affect the uptake of radioactivity.
The subcellular distribution of the radioactivity in liver homogenates was first examined by using differential centrifugation (Fig. 4 and Radioiodinated glucagons I and II isolated by two-step h.p.l.c. (Fig. 1) were submitted to radio-sequence analysis as described in the Materials and methods section. For each labelled peptide, the radioactivity liberated as the corresponding amino acid phenylthiohydantoin is plotted against the cycle of Edman degradation. the radioactivity was associated with the N and P fractions, the remainder being associated with the S fraction. Up to 20 min, there was a progressive decrease in the amount ofthe radioactivity associated with the N fraction, along with an increase in that present in the P fractions; the amount of radioactivity associated with the ML fraction increased only slightly, and that associated with the S fraction remained relatively unchanged. After 20 min, however, the amount of radioactivity associated with the ML and P fractions decreased, whereas that associated with the S fraction increased proportionately. Chloroquine treatment did not affect the distribution pattern of the radioactivity in the first 20 min, but caused an increase in the proportion of radioactivity associated with the ML and P fractions at 40 min, along with a correlative decrease of that associated with the S fraction. The uptake of radioactivity into plasma membranes and Golgiendosomal fractions derived from the P fraction was then studied (Fig. S and Table 3 ). Uptake of radioactivity into plasma membranes was maximal at 5 min, with a 5-fold enrichment and a 5 % recovery. Uptake of radioactivity into Golgi-endosomal fractions occurred more slowly and reached a maximum by 20 min, with enrichments of about 25-(light fraction), 150-(intermediate fraction) and 75-fold (heavy fraction), and corresponding recoveries of 0.5, 5.5 and 5.1 %. Chloroquine treatment did not affect the uptake of the radioactivity into plasma membranes, but caused a decrease in the enrichment of the radioactivity in Golgi-endosomal fractions at 5-20 min. However, because of higher protein recoveries, recoveries of radioactivity in Golgi-endosomal fractions of chloroquine-treated rats Table 2 . Recoveries of radioactivity in the nuclear (N), mitochondrial-lysosomal (ML), microsomal (P) and supernatant (S) fractions in control and chloroquine-treated rats Recoveries were calculated from relative activities (shown in Fig. 4 ) and protein yields with results expressed as the percentage of the radioactivity in the homogenate. Asterisks indicate a significant difference between control and chloroquine-treated animals (**P < 0.01; ***P < 0.001). To assess further the localization of the radioactivity associated with Golgi-endosomal fractions, the latter were subfractionated by the diaminobenzidine-induced density-shift protocol [19] , after which the distribution of the radioactivity was compared with that of galactosyltransferase. When Golgi-endosomal fractions loaded by the GalBSA-HRP conjugate were incubated with diaminobenzidine in the absence of H202, the radioactivity migrated as a peak of density of about 1.11 g -cm-3, which coincided with the peak for galactosyltransferase (Fig. 6) . In contrast, when the same incubation was carried out in the presence of H202, the peak of radioactivity was shifted to a density of about 1.15 g -cm-3, the distribution of galactosyltransferase remaining unaffected. These results identify endosomes as the structures containing glucagon in Golgiendosomal fractions.
To determine whether the radioactivity present in the ML fraction at late times was associated with lysosomes, its disVol. 272 tribution on sucrose gradients was studied and compared with that of acid phosphatase. As shown in Fig. 7(a) , the radioactivity was broadly distributed throughout the gradient with a peak at densities 1.11-1.13 g cm-, and a median density of 1.165 g -cm3. In contrast, acid phosphatase was recovered mainly at densities below 1. 1 g -cm-3, with a median density of 1.203 g * cm-3. In chloroquine-treated rats (Fig. 7b) , both the radioactivity and acid phosphatase were shifted towards lower densities (median densities of 1.128 and 1.169 g-cm-' respectively), but the relative amount of radioactivity overlapping with acid phosphatase was little affected. Comparison of the density-distribution histograms indicates that, regardless of chloroquine treatment, at least 55-60 % of the radioactivity associated with the ML fraction is intrinsic to structures which do not contain acid phosphatase, presumably endosomes. The integrity of the [125liodoglucagon associated with liver subcellular fractions was first characterized by TCA precipitation (Fig. 8) . At 2 min, about 90% of the radioactivity associated with the homogenate and the crude sedimentable fractions was TCA-precipitable, but only 70 % of that associated with the S fraction was TCA-precipitable. Later, there was a progressive loss of [1251] iodoglucagon integrity in most subcellular fractions, which was especially marked in the S fraction. However, the decrease in TCA-precipitability of the radioactivity in the P fraction occurred only after 20 min, and was preceded by a slight increase in TCA-precipitability. The radioactivity associated with Golgi-endosomal fractions was about 70-80 % TCA-precipitable at 5 min, and 80-95 % TCA-precipitable at later times, precipitability being higher in the heavy and intermediate fractions than in the light fraction. The radioactivity associated with plasma membranes remained at least 95 % TCA-precipitable regardless of time.
Chloroquine treatment little affected the TCA-precipitability of the radioactivity in homogenates and in the N, ML and S fractions, except for a significant increase in TCA-precipitability in homogenates at 40 min. Unexpectedly, at most times after injection, chloroquine treatment caused a slight but significant decrease in the TCA-precipitability of the radioactivity associated with the P fraction and the Golgi-endosomal fractions.
The integrity of the [251I]iodoglucagon associated with Golgiendosomal fractions of control and chloroquine-treated rats was further characterized by gel filtration and h.p.l.c., by using
[1251]iodoglucagon labelled at either the 10 or the 13 position (Fig. 9) . In control rats, about 95 % of the radioactivity was recovered as intact [125liodoglucagon; most of the remainder was eluted at the same position as monoiodotyrosine. In chloroquine-treated rats, there was a slight decrease in the indicating similar processing of the two ligands. The four major chloroquine-sensitive products were characterized by radio-sequence analysis (Fig. 10) [1251I]iodoglucagon is taken up in part into the liver and accumulates under a relatively intact form in non-lysosomal lowdensity endocytic structures. In the present studies, the involvement of these structures in the processing of glucagon has been further assessed in vivo and in a cell-free system using [1251I]iodoglucagon labelled at positions 10 [125lIiodoglucagon degradation as a function of pH of the medium.
was of little importance, since, as previously shown in studies with isolated hepatocytes [2] , the two isomers were processed identically by liver subcellular fractions.
The time-dependent changes in the subcellular distribution of [125I]iodoglucagon in control rats indicate that this ligand undergoes endocytosis. At early times, the sedimentable radioactivity in the homogenate was for the most part associated with the N and P fractions, a distribution typical for plasmamembrane markers, and was concentrated 6-fold in partially purified plasma membranes. Later, it accumulated progressively in the P and ML fractions, with a 20-150-fold concentration in low-density P subfractions. On analytical sucrose-density gradients, the distribution of radioactivity associated with the low-density P subfractions was density-shifted by diaminobenzidine cytochemistry, whereas the distribution of galactosyltransferase was unaffected. On similar gradients, at least 60 % of the radioactivity associated with the ML fraction at a late time was found to be associated with low-density structures that did not contain acid phosphatase. These findings confirm and extend previous results [10, 11] and identify low-density endosomes as one major subcellular site at which [125I]iodoglucagon is concentrated upon endocytosis.
The time-dependent decrease in the TCA-precipitability of the radioactivity associated with liver homogenates and crude subcellular fractions indicates that [251I]iodoglucagon taken up by the liver is progressively degraded. In addition, the rapid generation of TCA-soluble products in the S fraction suggests that this process occurs intracellularly, at least in part. However, throughout the time of study the radioactivity associated with the P, PM and Golgi-endosomal fractions remained at least 80-90 % TCA-precipitable; a paradoxical increase in TCAprecipitability was even observed at early post-injection times, probably reflecting a rapid movement of monoiodotyrosine and/or short peptides out of the liver. Furthermore, on gel filtration and h.p.l.c., most of the ['25Iliodoglucagon associated with Golgi-endosomal fractions retained integrity, monoiodotyrosine being the only degradation product detectable.
The inability to document extensive entry of internalized glucagon into lysosomes, also observed with insulin [26] , and the fact that [1251liodoglucagon associated with endosomes retains apparent integrity, could result from a rapid diffusion of degradation products out of these organelles. One theoretical way to overcome this drawback would be to link [1261] iodoglucagon to a labelled molecule that does not diffuse through the membrane of endocytic structures, such as [14C]sucrose [28] or ['25l ]iodotyramine-cellobiose [29] . Although this approach has been successfully applied to high-molecular-mass proteins, such as asialoglycoproteins [30] and formaldehyde-treated albumin [31] , it is unlikely to be applicable to a low-molecular-mass peptide such as glucagon. So far, most derivatives of glucagon have shown a drastic loss in the affinity of this peptide for its receptor [32] .
In a number of ligand-receptor systems, the weak base chloroquine has been shown to increase the accumulation of internalized ligand in acidic cell compartments, presumably by inhibiting the dissociation of ligand-receptor complexes and/or the subsequent degradation ofdissociated ligand [33] . At variance with previous observations with insulin [26, 27, 34] and prolactin [26, 34, 35] , chloroquine treatment caused only a minimal and late increase in glucagon accumulation in the liver endocytic structures and a paradoxical decrease in TCA-precipitability of the ligand associated with these fractions. In gel-filtration and h.p.l.c. studies, chloroquine treatment led to the appearance of multiple low-molecular-mass degradation products less hydrophobic than [1251] iodoglucagon; radio-sequence analysis of four of these products identified cleavages at bonds Ser2-Gln3, Although insulin internalized in liver cells is taken up and degraded in the same endocytic structures as glucagon [33, 40] , the fate of these peptides differs in several respects. First, in time studies, insulin associates more rapidly with endosomes than does glucagon, and is also more rapidly cleared from these structures [26, 34, 41, 42] . Secondly, presumably because of their larger size, insulin degradation products, unlike glucagon products, remain in part associated with endosomes [41] [42] [43] . Thirdly, the endosomal retention of undegraded ligand caused by chloroquine treatment is higher for insulin than for glucagon [26, 27] . Finally, in cell-free endosomes, the pH for maximal insulin degradation is about [5] [6] [38, 39] , a value higher than the pH for maximal glucagon degradation; this appears to reflect different sensitivities of ligand-receptor complexes to dissociation by a low pH (F. Authier & B. Desbuquois, unpublished work).
Because the integrity of the glucagon sequence beyond tyrosine-13 was not examined in the present work, it is difficult to compare the specificity of the endosomal degrading activity with that of other glucagon-degrading activities reported previously. However, none of the cleavage sites identified in this study correspond to the cleavage site described in studies with isolated dog and rat hepatocytes, which was shown to affect the Gln3-GIy4 bond [2, 3] . Likewise, the results described here do not Vol. 272 support the involvement ofthe glucagon-receptor-linked protease recently identified in dog plasma membranes, which was shown to cleave the Tyr'3-Leu'4 bond [8, 9] . Insulin protease, which cleaves the bond Thr5-Phe6 [44] , might be a better candidate, although it does not account for the cleavages at the 2-3 and 6-7 positions. Additional work is required to identify the cleavage sites in the glucagon sequence beyond tyrosine-13 and to characterize the glucagon-degrading activity associated with liver endosomes.
